
Opinion|Videos|December 19, 2025
ASCENT-03 and ASCENT-04 Sacituzumab Govitecan Safety Data Shared at SABCS 2025
Author(s)Laura Huppert, MD
Advertisement
Episodes in this series
Updated safety from the ASCENT-03 and ASCENT-04 trials were shared at the 2025 San Antonio Breast Cancer Symposium (SABCS). Both studies explored sacituzumab govitecan in the first-line setting for patients with triple-negative breast cancer, with ASCENT-03 exploring the ADC as a monotherapy and ASCENT-04 evaluating the ADC in combination with the PD-1 inhibitor pembrolizumab. In this video, Laura Huppert, MD, highlights the safety outcomes from the trials presented at SABCS 2025 and shares her expertise on managing adverse events associated with these treatments.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5



















